Alzheimer's disease (AD) pathology develops many years before the onset of cognitive
symptoms. Two pathological processes—aggregation of the amyloid-β (Aβ) peptide into …

Mass spectrometry-based proteomics empowers deep profiling of proteome and protein
posttranslational modifications (PTMs) in Alzheimer's disease (AD). Here we review the …

Our understanding of Alzheimer's disease (AD) pathophysiology remains incomplete. Here
we used quantitative mass spectrometry and coexpression network analysis to conduct the …

Alzheimer's disease (AD) is heterogenous at the molecular level. Understanding this
heterogeneity is critical for AD drug development. Here we define AD molecular subtypes …

Alzheimer's disease (AD) is a neurodegenerative disease with heterogenous
pathophysiological changes that develop years before the onset of clinical symptoms. These …

The repeated failures of amyloid-targeting therapies have challenged our narrow
understanding of Alzheimer's disease (AD) pathogenesis and inspired wide-ranging …

Disease modifying treatments for Alzheimer's disease (AD) constitute a major goal in
medicine. Current trends suggest that biomarkers reflective of AD neuropathology and …

Proteomic studies for Alzheimer's disease (AD) are instrumental in identifying AD pathways
but often focus on single tissues and sporadic AD cases. Here, we present a proteomic study …

Background Altered proteome profiles have been reported in both postmortem brain tissues
and body fluids of subjects with Alzheimer disease (AD), but their broad relationships with …

Data-driven analyses are increasingly valued in modern medicine. We integrate quantitative
proteomics and transcriptomics from over 1,000 post-mortem brains from six cohorts …